CompanyGraph
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- FinancialsAltman Z-Score 9.88: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.86BCNY277.06M · vs all stocks (USD)
Revenue (TTM)
350.56MCNY52.29M · vs all stocks (USD)
Profit Margin
-0.74%Beta
-0.0280xvs all stocks
52-Week Change
-40.68%vs all stocks
Market Capitalization
1.86BCNY277.06M · vs all stocks (USD)
Enterprise Value
1.29BCNY192.29M · vs all stocks (USD)
Price to Sales (TTM)
5.34xPrice to Book (MRQ)
1.98xEnterprise to Revenue
3.68xEnterprise to EBITDA
45.33xGross Margin
74.22%Profit Margin
-0.74%Operating Margin
-47.57%Return on Assets (TTM)
0.83%Return on Equity (TTM)
-0.36%Revenue (TTM)
350.56MCNY52.29M · vs all stocks (USD)
Revenue per Share (TTM)
0.6930CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-44.60%Gross Profit (TTM)
189.89MCNY28.32M · vs all stocks (USD)
EBITDA (TTM)
63.07MCNY9.41M · vs all stocks (USD)
Net Income (TTM)
-2.58MCNY-385.41K · vs all stocks (USD)
Operating Cash Flow (TTM)
-20.41MCNY-3.04M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-117.59MCNY-17.54M · vs all stocks (USD)
Payout Ratio
0.00%Revenue
383.75MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
153.73MCNYFY2025 · Dec 31, 2025Gross Profit
230.02MCNYFY2025 · Dec 31, 2025Operating Income
44.68MCNY6.66M · vs all stocks (USD)
Pre-tax Income
37.95MCNYFY2025 · Dec 31, 2025Income Tax Expense
7.47MCNYFY2025 · Dec 31, 2025Net Income
30.48MCNYFY2025 · Dec 31, 2025EBIT
38.14MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
63.07MCNYFY2025 · Dec 31, 2025Research & Development
9.04MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
130.13MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.74MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
566.42KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
189.40KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0601CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0601CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
507.11MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
507.11MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
30.48MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-72.92MCNYFY2025 · Dec 31, 2025Free Cash Flow
-182.83MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
163.84MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
30.48MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.25MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-111.58MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
5.94MCNYFY2025 · Dec 31, 2025Capital Expenditures
-109.92MCNYFY2025 · Dec 31, 2025Purchase of Investments
-37.60MCNYFY2025 · Dec 31, 2025Sale of Investments
7.38MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-140.14MCNYFY2025 · Dec 31, 2025Other Financing Charges
-38.25MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-38.25MCNYFY2025 · Dec 31, 2025Shares Outstanding
507.51MSharesUpdated Sep 19, 2026Float Shares
301.13MSharesUpdated Sep 19, 2026% Held by Insiders
24.66%vs all stocks
% Held by Institutions
0.26%vs all stocks
Total Cash (MRQ)
128.45MCNY19.16M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3400CNYUpdated Sep 19, 2026Total Debt (MRQ)
20.00MCNY2.98M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0284xCurrent Ratio (MRQ)
4.58xBook Value per Share (MRQ)
1.87CNYUpdated Sep 19, 2026Total Assets
849.23MCNY126.67M · vs all stocks (USD)
Total Current Assets
502.68MCNYFY2025 · Dec 31, 2025Total Liabilities
131.30MCNYFY2025 · Dec 31, 2025Total Non-current Assets
346.56MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
34.92MCNYFY2025 · Dec 31, 2025Total Current Liabilities
96.38MCNYFY2025 · Dec 31, 2025Cash
163.14MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.51MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
164.65MCNYFY2025 · Dec 31, 2025Other Short-term Investments
12.47MCNYFY2025 · Dec 31, 2025Accounts Receivable
136.72MCNYFY2025 · Dec 31, 2025Inventory
74.04MCNYFY2025 · Dec 31, 2025Accounts Payable
26.86MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.84MCNYFY2025 · Dec 31, 2025Common Stock (Book)
507.51MCNYFY2025 · Dec 31, 2025Retained Earnings
129.50MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
717.93MCNY107.09M · vs all stocks (USD)
Treasury Stock
70.00MCNYFY2025 · Dec 31, 202552-Week Low
2.90CNYUpdated Sep 19, 202652-Week High
8.43CNYUpdated Sep 19, 202652-Week Change
-40.68%vs all stocks
Beta
-0.0280xvs all stocks
50-Day MA
3.41CNYUpdated Sep 19, 2026200-Day MA
5.50CNYUpdated Sep 19, 2026Avg 10-Day Volume
7.62MSharesUpdated Sep 19, 2026Avg 30-Day Volume
6.51MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-0.0100CNYUpdated Sep 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.74Profit Margin: -0.01
Financial Health
Altman Z-Score 9.88: safe zoneNotable
Altman Z-Score: 9.88
High earnings qualityNotable
Earnings Quality Score: 0.82
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
Invivyd Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tiansheng Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Qingdao Eastsoft Communication Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Sunwoda Electronic Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Shanghai Cooltech Power Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline